Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 0: clinchem.2004.032144v1, 2004; 10.1373/clinchem.2004.032144
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2004.032144v1
50/8/1301    most recent
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Carrigan, S. D.
Right arrow Articles by Tabrizian, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Carrigan, S. D.
Right arrow Articles by Tabrizian, M.

Received on February 2, 2004
Accepted on May 5, 2004

Review

Toward Resolving the Challenges of Sepsis Diagnosis

Shawn D. Carrigan 1, George Scott 2, Maryam Tabrizian 1*

1 McGill University, Biomedical Engineering Department, Montreal, QC, Canada
2 MDS Pharma Services, St. Laurent, QC, Canada

Sepsis in the United States has an estimated annual healthcare cost of $16.7 billion and leads to 120 000 deaths. Insufficient development in both medical diagnosis and treatment of sepsis has led to continued growth in reported cases of sepsis over the past two decades with little improvement in mortality statistics. Efforts over the last decade to improve diagnosis have unsuccessfully sought to identify a "magic bullet" proteic biomarker that provides high sensitivity and specificity for infectious inflammation. More recently, genetic methods have made tracking regulation of the genes responsible for these biomarkers possible, giving current research new direction in the search to understand how host immune response combats infection. Despite the breadth of research, inadequate treatment as a result of delayed diagnosis continues to affect approximately one fourth of septic patients. In this report we review past and present diagnostic methods for sepsis and their respective limitations, and discuss the requirements for more timely diagnosis as the next step in curtailing sepsis-related mortality. We also present a proposal toward revision of the current diagnostic paradigm to include real-time immune monitoring.


The following articles in journals at HighWire Press have cited this article:


Home page
 Am. J. Respir. Crit. Care Med.Home page
B. M. P. Tang, A. S. McLean, I. W. Dawes, S. J. Huang, and R. C. Y. Lin
The Use of Gene-Expression Profiling to Identify Candidate Genes in Human Sepsis
Am. J. Respir. Crit. Care Med., October 1, 2007; 176(7): 676 - 684.
[Abstract] [Full Text] [PDF]

Home page
 Innate ImmunityHome page
W. van der Meer, P. Pickkers, C. S. Scott, J. G. van der Hoeven, and J. K. Gunnewiek
Hematological indices, inflammatory markers and neutrophil CD64 expression: comparative trends during experimental human endotoxemia
Innate Immunity, April 1, 2007; 13(2): 94 - 100.
[Abstract] [PDF]

Home page
 Clin. Chem.Home page
K. Kofoed, U. V. Schneider, T. Scheel, O. Andersen, and J. Eugen-Olsen
Development and Validation of a Multiplex Add-On Assay for Sepsis Biomarkers Using xMAP Technology
Clin. Chem., July 1, 2006; 52(7): 1284 - 1293.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
E. Magid, H. Guldager, D. Hesse, and M. S. Christiansen
Monitoring Urinary Orosomucoid in Acute Inflammation: Observations on Urinary Excretion of Orosomucoid, Albumin, {alpha}1-Microglobulin, and IgG
Clin. Chem., November 1, 2005; 51(11): 2052 - 2058.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
D. Stengel, K. Bauwens, D. Keh, H. Gerlach, A. Ekkernkamp, R. Tauber, and T. Kerner
Prognostic Value of an Early Soluble L-Selectin (sCD62L) Assay for Risk Assessment in Blunt Multiple Trauma: A Metaanalysis
Clin. Chem., January 1, 2005; 51(1): 16 - 24.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2004 by the American Association for Clinical Chemistry.